Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Daratumumab with Dose-Attenuated VRd in Elderly Newly Diagnosed Multiple Myeloma
NCT04052880Phase 2Completed
- Start
- Oct 2019
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM). Started Oct 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04052880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052880.